Why U.S. Stocks Are Trading Higher, Manufacturing Report And More
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Friday.
Here’s Why VerifyMe Shares Are Trading Higher Today
VerifyMe, Inc (NASDAQ:VRME) elected not to extend the period for a special purpose acquisition company (SPAC) merger with G3 VRM Acquisition Corp (NASDAQ:GGGVU). …
Billionaire Beau Wrigley Faces Another Cannabis Lawsuit, This Time Worth $80M, Seeks Arbitration
Billionaire William “Beau” Wrigley Jr, heir to the Wrigley chewing gum fortune, has requested arbitration in a failed Parallel deal to buy six Chicago cannabis companies.
Jim Cramer Says This Stock Is ‘Too Risky’
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Cadre Holdings Inc (NYSE: CDRE) as it "makes things, does stuff, sells at a profit, gives you money back."
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
Here's a roundup of top developments in the biotech space over the last 24 hours:
Endo Posts Disappointing Data From Frozen Shoulder Trial
Endo International plc (NASDAQ:ENDP) has announced topline results from its Phase 2 study of collagenase clostridium histolyticum (CCH) in participants with…
Flower One Restructures Its Term Debt And Master Lease
Flower One Holdings Inc. (OTCQX: FLOOF) (CSE:FONE) (FSE: F11) restructured its term debt and its master lease.
TikTok’s Smaller US Rival Files For IPO
Short video app Triller Inc has confidentially filed for an initial public offering with the U.S. SEC. Recently, Triller terminated its merger with…
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.
Akerna Shares Dip 53%, Here’s 78 Biggest Movers From Yesterday
Gainers
Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical study of REVTx-99b for the treatment of allergic rhinitis.